Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 44

HOS-109539 · Präparat HOS-093201

300 mg QD (coadministered Phenytoin Cmax  67% Phenytoin may be with voriconazole 400 mg Phenytoin AUC  81% coadministered with BID)* Compared to voriconazole 200 mg voriconazole if the maintenance BID, dose of voriconazole is increased Voriconazole Cmax  34% to 5 mg/kg IV BID or from Voriconazole AUC  39% 200 mg to 400 mg oral BID (100 mg to 200 mg oral BID in patients less than 40 kg) (see section 4.2). Antidiabetics Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should [CYP2C9 substrates] cause hypoglycaemia. be considered. Anti-fungals Fluconazole (200 mg QD) Voriconazole Cmax  57% The reduced dose and/or [CYP2C9, CYP2C19 and Voriconazole AUC  79% frequency of voriconazole and CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate Fluconazole AUC ND this effect have not been established. Monitoring for voriconazole-associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole. Antihistamines Astemizole Although not studied, increased Contraindicated (see section [CYP3A4 substrate] plasma concentrations of 4.3) astemizole can lead to QTc prolongation and rare occurrences of torsades de pointes.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) glucose (HOS-088412) lead (HOS-085592) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) phenytoin (HOS-084531) tolbutamide (HOS-086568)